

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 38/51</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/13830</b> <b>(43) International Publication Date:</b> 26 May 1995 (26.05.95)
<b>(21) International Application Number:</b> PCT/US94/13343 <b>(22) International Filing Date:</b> 17 November 1994 (17.11.94) <b>(30) Priority Data:</b> 153,873 17 November 1993 (17.11.93) US <b>(71) Applicants:</b> MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US). CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 55 Shattuck Street, Boston, MA 02115 (US). <b>(72) Inventors:</b> SASISEKHARAN, Ramnath; 118 Ridge Street, Arlington, MA 02174 (US). MOSES, Marsha, A.; 64 Dean Road, Brookline, MA 02146 (US). NUGENT, Matthew, A.; 6 Jeffrey Circle, Bedford, MA 01730 (US). COONEY, Charles, L.; 35 Chestnut Place, Brookline, MA 02146 (US). LANGER, Robert, S.; 77 Lombard Street, Newton, MA 02158 (US). <b>(74) Agents:</b> PABST, Patrea, L. et al.; Arnall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3400 (US).		<b>(81) Designated States:</b> CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD FOR INHIBITING ANGIOGENESIS USING HEPARINASE		
<b>(57) Abstract</b> <p>Pharmaceutical compositions for delivering an effective dose to a desired site of a heparinase. These compositions are based on the discovery that heparinase alone can inhibit angiogenesis. The effective dosage is dependent not only on the heparinase, but also on the method and means of delivery, which can be localized or systemic. For example, in some applications, as in the treatment of psoriasis or diabetic retinopathy, the inhibitor is delivered in a topical ophthalmic carrier. In other applications, as in the treatment of solid tumors, the inhibitor is delivered by means of a biodegradable, polymeric implant.</p>		